Responses
Regular and Young Investigator Award Abstracts
Clinical Trial Completed
609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.
